Walter D Fairlie
Overview
Explore the profile of Walter D Fairlie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
352
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Atkin-Smith G, Santavanond J, Light A, Rimes J, Samson A, Er J, et al.
Nat Commun
. 2024 Oct;
15(1):8802.
PMID: 39438460
Endothelial cells are integral components of all vasculature within complex organisms. As they line the blood vessel wall, endothelial cells are constantly exposed to a variety of molecular factors and...
2.
Chueh A, Tse J, Dickinson M, Ioannidis P, Jenkins L, Togel L, et al.
Clin Cancer Res
. 2023 Sep;
29(18):3826.
PMID: 37712140
No abstract available.
3.
Harris T, Liao Y, Shi W, Evangelista M, Pal B, Puthalakath H, et al.
Cancer Med
. 2023 May;
12(12):13522-13537.
PMID: 37148543
Background: Monepantel is an anti-helminthic drug that also has anti-cancer properties. Despite several studies over the years, the molecular target of monepantel in mammalian cells is still unknown, and its...
4.
Arulananda S, OBrien M, Evangelista M, Jenkins L, Poh A, Walkiewicz M, et al.
Cell Death Discov
. 2021 May;
7(1):122.
PMID: 34050131
Malignant pleural mesothelioma (MPM) is an aggressive cancer with treatment limited to Cisplatin and Pemetrexed chemotherapy. Recently, we showed that drugs targeting the BCL-2-regulated apoptosis pathway could kill MPM cell...
5.
Gangoda L, Teh C, Dengler M, Best S, Weeden C, Tai L, et al.
Cell Death Differ
. 2019 Nov;
27(2):826-828.
PMID: 31719651
No abstract available.
6.
Chueh A, Tse J, Dickinson M, Ioannidis P, Jenkins L, Togel L, et al.
Clin Cancer Res
. 2017 Jun;
23(18):5573-5584.
PMID: 28611196
Histone deacetylase inhibitors (HDACi) are epigenome-targeting small molecules approved for the treatment of cutaneous T-cell lymphoma and multiple myeloma. They have also demonstrated clinical activity in acute myelogenous leukemia, non-small...
7.
Young A, Law A, Castillo L, Chong S, Cullen H, Koehler M, et al.
Breast Cancer Res
. 2016 Dec;
18(1):125.
PMID: 27931239
Background: Metastatic disease is largely resistant to therapy and accounts for almost all cancer deaths. Myeloid cell leukemia-1 (MCL-1) is an important regulator of cell survival and chemo-resistance in a...
8.
Rohrbeck L, Gong J, Lee E, Kueh A, Behren A, Tai L, et al.
Cell Death Differ
. 2016 Oct;
23(12):2054-2062.
PMID: 27689874
A large proportion of melanomas harbour the activating BRAF mutation that renders these cells dependent on MAPK signalling for their survival. Although the highly specific and clinically approved BRAF kinase...
9.
Merino D, Khaw S, Glaser S, Anderson D, Belmont L, Wong C, et al.
Blood
. 2012 Apr;
119(24):5807-16.
PMID: 22538851
The BH3-mimetic ABT-737 and an orally bioavailable compound of the same class, navitoclax (ABT-263), have shown promising antitumor efficacy in preclinical and early clinical studies. Although both drugs avidly bind...
10.
Merino D, Giam M, Hughes P, Siggs O, Heger K, OReilly L, et al.
J Cell Biol
. 2009 Aug;
186(3):355-62.
PMID: 19651893
Proteins of the Bcl-2 family are critical regulators of apoptosis, but how its BH3-only members activate the essential effectors Bax and Bak remains controversial. The indirect activation model suggests that...